These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

784 related articles for article (PubMed ID: 33894099)

  • 1. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
    Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
    Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2.
    Xiang Y; Nambulli S; Xiao Z; Liu H; Sang Z; Duprex WP; Schneidman-Duhovny D; Zhang C; Shi Y
    Science; 2020 Dec; 370(6523):1479-1484. PubMed ID: 33154108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Basis for Evasion of New SARS-CoV-2 Variants from the Potent Virus-Neutralizing Nanobody Targeting the S-Protein Receptor-Binding Domain.
    Sluchanko NN; Shcheblyakov DV; Varfolomeeva LA; Favorskaya IA; Dolzhikova IV; Korobkova AI; Alekseeva IA; Esmagambetov IB; Derkaev AA; Prokofiev VV; Zorkov ID; Logunov DY; Gintsburg AL; Popov VO; Boyko KM
    Biochemistry (Mosc); 2024 Jul; 89(7):1260-1272. PubMed ID: 39218023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational redesign of Fab CC12.3 with substantially better predicted binding affinity to SARS-CoV-2 than human ACE2 receptor.
    Treewattanawong W; Sitthiyotha T; Chunsrivirot S
    Sci Rep; 2021 Nov; 11(1):22202. PubMed ID: 34772947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational design of SARS-CoV-2 peptide binders with better predicted binding affinities than human ACE2 receptor.
    Sitthiyotha T; Chunsrivirot S
    Sci Rep; 2021 Aug; 11(1):15650. PubMed ID: 34341401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
    Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L
    Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants.
    Yang Z; Wang Y; Jin Y; Zhu Y; Wu Y; Li C; Kong Y; Song W; Tian X; Zhan W; Huang A; Zhou S; Xia S; Tian X; Peng C; Chen C; Shi Y; Hu G; Du S; Wang Y; Xie Y; Jiang S; Lu L; Sun L; Song Y; Ying T
    Signal Transduct Target Ther; 2021 Nov; 6(1):378. PubMed ID: 34732694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2.
    Yao H; Cai H; Li T; Zhou B; Qin W; Lavillette D; Li D
    PLoS Pathog; 2021 Mar; 17(3):e1009328. PubMed ID: 33657135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.
    Mercurio I; Tragni V; Busto F; De Grassi A; Pierri CL
    Cell Mol Life Sci; 2021 Feb; 78(4):1501-1522. PubMed ID: 32623480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain.
    He L; Tai W; Li J; Chen Y; Gao Y; Li J; Sun S; Zhou Y; Du L; Zhao G
    Viruses; 2019 Feb; 11(2):. PubMed ID: 30791410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies.
    Wang WB; Liang Y; Jin YQ; Zhang J; Su JG; Li QM
    J Mol Graph Model; 2021 Dec; 109():108035. PubMed ID: 34562851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.
    Wu X; Cheng L; Fu M; Huang B; Zhu L; Xu S; Shi H; Zhang D; Yuan H; Nawaz W; Yang P; Hu Q; Liu Y; Wu Z
    Cell Rep; 2021 Oct; 37(3):109869. PubMed ID: 34644535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.
    Lu Q; Zhang Z; Li H; Zhong K; Zhao Q; Wang Z; Wu Z; Yang D; Sun S; Yang N; Zheng M; Chen Q; Long C; Guo W; Yang H; Nie C; Tong A
    J Nanobiotechnology; 2021 Jan; 19(1):33. PubMed ID: 33514385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies.
    Shah M; Woo HG
    Front Immunol; 2021; 12():830527. PubMed ID: 35140714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deconstructing SARS-CoV-2 neutralization: A modular molecular framework for computational design and comparison of antibodies and nanobodies targeting the spike RBD.
    Tragni V; Mercurio I; Paoletti DP; Onofrio A; Laera L; Cafferati Beltrame L; Sgobba MN; Guerra L; Volpicella M; De Grassi A; Elia G; Pierri CL
    J Med Virol; 2023 Jun; 95(6):e28875. PubMed ID: 37338047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational design of novel nanobodies targeting the receptor binding domain of variants of concern of SARS-CoV-2.
    Longsompurana P; Rungrotmongkol T; Plongthongkum N; Wangkanont K; Wolschann P; Poo-Arporn RP
    PLoS One; 2023; 18(10):e0293263. PubMed ID: 37874836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.